KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesChange in ReceivablesChange in TaxesChange in TaxesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionExchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesNet Cash FlowNet Cash FlowOther Working Capital ChangesOther Working Capital ChangesShare-based CompensationShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

AbCellera Biologics (ABCL) Capital Expenditures (2020 - 2025)

AbCellera Biologics' Capital Expenditures history spans 6 years, with the latest figure at $9.8 million for Q4 2025.

  • For the quarter ending Q4 2025, Capital Expenditures fell 37.02% year-over-year to $9.8 million, compared with a TTM value of $42.8 million through Dec 2025, down 45.44%, and an annual FY2025 reading of $42.8 million, down 45.44% over the prior year.
  • Capital Expenditures for Q4 2025 was $9.8 million at AbCellera Biologics, up from $8.9 million in the prior quarter.
  • The five-year high for Capital Expenditures was $36.8 million in Q2 2021, with the low at $3.6 million in Q1 2021.
  • Average Capital Expenditures over 5 years is $16.4 million, with a median of $14.5 million recorded in 2022.
  • Year-over-year, Capital Expenditures soared 893.9% in 2021 and then crashed 55.94% in 2025.
  • Tracing ABCL's Capital Expenditures over 5 years: stood at $9.4 million in 2021, then soared by 30.75% to $12.3 million in 2022, then increased by 17.04% to $14.4 million in 2023, then increased by 8.31% to $15.6 million in 2024, then plummeted by 37.02% to $9.8 million in 2025.
  • Per Business Quant, the three most recent readings for ABCL's Capital Expenditures are $9.8 million (Q4 2025), $8.9 million (Q3 2025), and $13.4 million (Q2 2025).